CD274 and neoplasm: Particularly noteworthy are bispecific antibodies, such as PD-L1/CD3 (Bispecific T-cell Engagers) BiTEs, which simultaneously relieve immune suppression and redirect T cells toward tumor killing, achieving dual functional enhancement in solid tumors (162).